EditorialWhere will new drugs come from?
References (0)
Cited by (20)
What Are Current Main Obstacles to Reach Drug Approval?
2015, Re-Engineering Clinical Trials: Best Practices for Streamlining the Development ProcessApplication of pharmacogenomics and other new technologies to drug development
2013, Medicina ClinicaInnovation and the burden of disease: Retrospective observational study of new and emerging health technologies reported by the EuroScan network from 2000 to 2009
2012, Value in HealthCitation Excerpt :The development of new health technologies might be expected to focus on diseases with high morbidity and mortality, to reflect areas of greater burden. However, because the innovation process is long, costly [3,4], often unsuccessful, and largely commercially driven, innovation typically reflects all the factors influencing investment return, of which burden of disease is just one [5–7]. The existing evidence of a positive relationship between burden of disease and innovation is based mainly on input measures of innovation such as public and charitable research and development (R&D) funding [8,9].
A challenging drug development process in the era of personalized medicine
2011, Drug Discovery TodayCitation Excerpt :The way that many drugs are being developed today seems to be less optimal and, in general, the productivity of the R&D departments seems to be decreasing. It has been estimated that around US$60 billion, of the US$85 billion spent globally each year on R&D, are wasted owing to failures during the drug development process [33]. Further, if we look at the output from the pipelines in the different pharma and biotech companies it has been declining over the past one or two decades, whereas costs have increased during the same period.
New drug development
2011, The LancetNew drug development
2011, The Lancet